Trevi Therapeutics, Inc. (TRVI)
After hours:
Trevi Therapeutics, Inc.
195 Church Street
16th Floor
New Haven, CT 06510
United States
203 304 2499
https://www.trevitherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 26
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Jennifer L. Good | Co-Founder, CEO, President & Director | 835.9k | N/A | 1965 |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 551.43k | N/A | 1953 |
| Dr. James V. Cassella Ph.D. | Chief Development Officer | 50k | N/A | 1955 |
| Ms. Lisa Delfini | Chief Financial Officer | N/A | N/A | 1970 |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | N/A | N/A | 1978 |
| Katie McManus | Communications Manager | N/A | N/A | N/A |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | N/A | N/A | N/A |
| Ms. Danine Summers | Vice President of Medical Affairs | N/A | N/A | 1958 |
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Corporate Governance
Trevi Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 8.
